Compounds > febuxostat
Page last updated: 2024-09-04

febuxostat and s 1033

febuxostat has been researched along with s 1033 in 3 studies

Compound Research Comparison

Studies
(febuxostat)		Trials
(febuxostat)		Recent Studies (post-2010)
(febuxostat)		Studies
(s 1033)		Trials
(s 1033)		Recent Studies (post-2010) (s 1033)
8181337101,4071471,074

Protein Interaction Comparison

ProteinTaxonomyfebuxostat (IC50)s 1033 (IC50)
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)4.7
Solute carrier family 22 member 3Homo sapiens (human)0.5
Tyrosine-protein kinase ABL1Homo sapiens (human)0.34
Low-density lipoprotein receptorHomo sapiens (human)9.8
FibronectinHomo sapiens (human)0.12
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)1.1
Tyrosine-protein kinase LckHomo sapiens (human)0.1082
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.677
Tyrosine-protein kinase LynHomo sapiens (human)1.281
Cytochrome P450 3A4Homo sapiens (human)0.58
Macrophage colony-stimulating factor 1 receptorMus musculus (house mouse)0.534
Platelet-derived growth factor receptor betaHomo sapiens (human)0.052
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.1115
Breakpoint cluster region proteinHomo sapiens (human)0.0575
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)1.01
Solute carrier family 2, facilitated glucose transporter member 4Mus musculus (house mouse)0.042
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)1.0905
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.0368
Ephrin type-A receptor 2Homo sapiens (human)0.033
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)9.548
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)4.7
Epithelial discoidin domain-containing receptor 1Homo sapiens (human)0.0371
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.2879
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)4.7
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)4.7
Discoidin domain-containing receptor 2Homo sapiens (human)0.0289
Proprotein convertase subtilisin/kexin type 9Homo sapiens (human)9.8
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)2.5

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF1
Abumiya, M; Fujioka, Y; Ito, F; Kameoka, Y; Kobayashi, T; Miura, M; Takahashi, N; Takahashi, S; Yoshioka, T1

Reviews

2 review(s) available for febuxostat and s 1033

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
    European journal of medicinal chemistry, 2022, Jul-05, Volume: 237

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells

2022

Other Studies

1 other study(ies) available for febuxostat and s 1033

ArticleYear
The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
    International journal of hematology, 2021, Volume: 113, Issue:1

    Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Proliferation; Cell Survival; Drug Therapy, Combination; Febuxostat; Gene Expression; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Targeted Therapy; Neoplasm Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines

2021